Covid-19 roundup: Can­cer biotech to sub­mit EUA for Covid drug; FDA OKs Eli Lil­ly JAK in­hibitor

As vac­cine talk wanes, re-pur­posed treat­ments take cen­ter stage for Covid-19.

Veru, which start­ed out as a can­cer out­fit, plans to re­quest an EUA for its drug sabiz­ab­u­lin as a Covid-19 treat­ment for pa­tients at high risk for acute res­pi­ra­to­ry dis­tress syn­drome (ARDS), it an­nounced to­day.

Last month, Veru said its Phase III study for its Covid-19 treat­ment was shut down by an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee due to the drug’s “over­whelm­ing ef­fi­ca­cy.” Ac­cord­ing to the com­pa­ny, sabiz­ab­u­lin re­duced deaths by 55% com­pared to the stan­dard of care group, which re­ceived remde­sivir, dex­am­etha­sone, an­ti­bod­ies, and JAK in­hibitors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.